medi5752: first-in-human trial of a novel pd-1 and ctla-4 bispecific checkpoint inhibitor
Published 2 years ago • 389 plays • Length 3:36Download video MP4
Download video MP3
Similar videos
-
1:56
medi5752: novel pd-1/ctla-4 bispecific checkpoint inhibitor for advanced solid tumors
-
0:18
future research directions for the novel pd-1 and ctla-4 bispecific checkpoint inhibitor, medi5752
-
2:07
immune checkpoint inhibitors, the next generation cancer therapy - creative biolabs
-
12:12
immune checkpoint proteins
-
4:00
cancer immunotherapy - pd-1 and pd-l1
-
4:10
combination of medi0680, an anti-pd-1 antibody, with durvalumab, an anti-pd-l1 antibody
-
6:56
all you need to know about pd-l1 by immunohistochemistry
-
8:17
immune checkpoint inhibitors
-
5:01
low dose immunotherapy - sudha's recovery
-
5:33
cancer immune checkpoint inhibitors
-
1:52
what are checkpoint inhibitors
-
40:21
extending horizons with immune checkpoint inhibitors in small cell lung cancer: 2022 perspectives
-
26:32
standard and alternative dosing regimens of immunotherapies and combinations in modern oncology
-
15:11
understanding cancer immunotherapy
-
3:59
the selection of pd-l1 escape variants in microsatellite stable metastatic crc on avelumab treatment
-
5:53
are pd-1/pd-l1 immune checkpoint inhibitors completely interchangeable in lung cancer? (bmic-015)
-
3:50
testing the safety and efficacy of the pd-l1 antibody durvalumab
-
1:58
battling breast cancer: understanding the tumor microenvironment
-
0:46
immune checkpoint inhibitors: recent progress and potential biomarkers - 3iv pd-l1 overexpression
-
25:42
differential tumour microenvironment response to pd 1 checkpoint inhibition - by shinjini
-
3:46
immunotherapy as first-line treatment